Biocon Biologics receives positive CHMP opinion for Pertuzumab biosimilar

Used in treatment of HER2-positive breast cancer across multiple disease stages
Read more at the source

Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.